Key result
The Microlife WatchBP Office device accurately measured blood pressure in patients with atrial fibrillation, with a mean difference of 0.0 ± 7.7 mmHg for systolic and 0.2 ± 7.0 mmHg for diastolic.
Why the study?
Blood pressure measurement in patients with AF is problematic, automated monitors are considered inaccurate, and the optimal validation procedure in AF is questionable.
Does the Microlife WatchBP Office device accurately measure blood pressure compared to reference standards in patients with sustained atrial fibrillation?
Observational (n=35)
Does the Microlife WatchBP Office device accurately measure blood pressure compared to reference standards in patients with sustained atrial fibrillation?
Mean Difference: 0
The Microlife WatchBP Office device with an AF-specific algorithm accurately measures blood pressure in patients with sustained atrial fibrillation, meeting validation criteria even in those with high BP variability.
Supports accurate BP measurement by this device in AF; leaves open need for prospective trials before practice change.
OBJECTIVES: Blood pressure (BP) measurement in atrial fibrillation (AF) patients is problematic and automated monitors are regarded as inaccurate. The optimal procedure for validating BP monitors in AF is questionable. This study evaluated the accuracy of a novel professional oscillometric upper-arm cuff device (Microlife WatchBP Office), which has an algorithm for detecting AF and then applies an AF-specific BP measurement algorithm. BP variability, which is inherently increased in AF patients, was considered in the analysis. METHODS: Subjects with sustained AF were included in a validation study using the same arm sequential measurement method of the Universal Standard (ISO 81060-2:2018) for special populations. Analysis was performed in all subjects and separately in those with and without high reference BP variability (>12/8 mmHg SBP/DBP). RESULTS: Thirty-five subjects with 105 paired test/reference BP measurements were included (mean age 76.3 ± 8.4 years, reference SBP/DBP 128.2 ± 19.5/72.5 ± 12.1 mmHg, pulse rate 68.3 ± 14.9 bpm). Validation Criterion 1 (mean difference ± SD) was 0.0 ± 7.7/0.2 ± 7.0 mmHg in all 105 BP pairs (threshold ≤5 ± 8 mmHg). Criterion 1 was 0.5 ± 6.1/-0.2 ± 6.8 mmHg in 18 subjects (54 BP pairs) with low reference BP variability and -0.6 ± 9.2/0.6 ± 7.3 mmHg in 17 (51 pairs) with high variability. Criterion 1 did not differ in pulse rate < 70 vs. ≥ 70 bpm Validation Criterion 2 (SD of differences for 35 individuals) was 5.38/6.20 mmHg (SBP/DBP; threshold ≤6.95/6.95). CONCLUSION: A technology which detects AF and activates an AF-specific BP measurement algorithm introduces a challenging solution for clinical practice. Validation of BP monitors in AF patients should not ignore their inherently high BP variability.
No takes yet. Share an insight, caveat, or question.
Stergiou et al. (2020) conducted an observational in Atrial fibrillation (n=35). Microlife WatchBP Office device vs. Reference blood pressure measurements was evaluated on Validation Criterion 1 (mean difference ± SD of blood pressure measurements) (MD 0.0 ± 7.7 mmHg (SBP) and 0.2 ± 7.0 mmHg (DBP)). The Microlife WatchBP Office device accurately measured blood pressure in patients with atrial fibrillation, with a mean difference of 0.0 ± 7.7 mmHg for systolic and 0.2 ± 7.0 mmHg for diastolic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: